Non Insulin Dependent Diabetes Clinical Trial
Official title:
Curcumin Supplementation and Type 2 Diabetes
| NCT number | NCT02529969 |
| Other study ID # | 615 |
| Secondary ID | |
| Status | Recruiting |
| Phase | Phase 2/Phase 3 |
| First received | August 19, 2015 |
| Last updated | August 19, 2015 |
| Start date | July 2015 |
Diabetes mellitus is the most common endocrine disorder, causes many complications such as micro- and macro-vascular diseases. Various kinds of antidiabetic drugs have been developed, but most of them have side effects. Recently, the use of natural plant products has gained more attention among scientists in order to prevent diabetic vascular complications. Curcumin is a natural yellow product derived from the turmeric rhizome which has shown to be non-toxic and exhibits various bio¬logical activities such as anti-oxidant, anti-inflammatory, anti-carcinogenic, and anti-diabetic effects. Curcumin is effective in reducing glycemic index and hyperlipidemia in rodent models and is relatively inexpensive and safe. Most of the studies conducted on animal model, and just a few of them are on human model. The present study was planned to evaluate the effects of curcumin supplementation on serum levels of lipid profile and inflammatory markers in patients with type 2 diabetes
| Status | Recruiting |
| Enrollment | 50 |
| Est. completion date | |
| Est. primary completion date | January 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 40 Years to 65 Years |
| Eligibility |
Inclusion Criteria: 1. Tendency to participate 2. Age range of 40-65 3. Suffering from diabetes type 2 ( between 1 to 10 yeares) 4. BMI 18/5-30 5. Patients with diabetes who administer oral hypoglycemic agents and do not use Exclusion Criteria: 1. patients with liver diseases 2. patients with kidney diseases 3. patients with inflammatory diseases 4. patients with liver diseases 5. Administering herbal agents 6. Administering multivitamins and minerals in past 3 months |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Iran, Islamic Republic of | NNFTRI clinic | Tehran |
| Lead Sponsor | Collaborator |
|---|---|
| National Nutrition and Food Technology Institute |
Iran, Islamic Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Triglyceride | 12 weeks | No | |
| Secondary | C-Reactive Protein | 12 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03073343 -
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
|
N/A | |
| Completed |
NCT02529982 -
Curcumin Supplementation and Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT01745900 -
Evaluation and Comparison of Noninvasive Blood Glucose Concentrations
|
N/A | |
| Completed |
NCT00835861 -
Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes
|
Phase 2 |